Manganese catalyst enables exploration of the magic methyl effect

Corcoran, Emily B.; Schultz, Danielle M.

doi:10.1038/d41586-020-01167-1

NEWS AND VIEWS
29 April 2020

Manganese catalyst enables exploration of the magic methyl effect

The addition of a methyl group to a drug molecule can greatly alter the drug’s pharmacological properties. A catalyst has been developed that enables this ‘magic methyl effect’ to be rapidly explored for drug discovery.

Emily B. Corcoran⁰ &
Danielle M. Schultz¹

Emily B. Corcoran
1. Emily B. Corcoran is in Process Research and Development, Merck & Co., Inc., Boston, Massachusetts 02115, USA.
View author publications

You can also search for this author in PubMed Google Scholar
Danielle M. Schultz
1. Danielle M. Schultz is in Process Research and Development, Merck & Co., Inc., Kenilworth, New Jersey 07033, USA.
View author publications

You can also search for this author in PubMed Google Scholar

Access through your institution

Buy or subscribe

Developing a small-molecule drug requires iterations of building and testing new compounds to find one that strikes the right balance of pharmacological properties. The process typically takes more than 10 years and costs billions of dollars, because, for every 5,000 compounds made and tested, only one will become an approved drug¹^,². Indeed, a high-school basketball player is twice as likely to end up playing in the US professional league as any single compound tested in a drug-discovery programme is to become a marketed drug (see go.nature.com/2v8pnfm). One approach to accelerating drug discovery is late-stage functionalization, in which previously prepared test compounds are decorated with new atoms in the hope of favourably adjusting their pharmacological properties. Writing in Nature, Feng et al.³ report an outstanding advance towards this long-standing and historically challenging strategy.

Access options

Access through your institution

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 580, 592-593 (2020)

doi: https://doi.org/10.1038/d41586-020-01167-1

References

Pritchard, J. F. et al. Nature Rev. Drug Discov. 2, 542–553 (2003).
Article PubMed Google Scholar
Biopharmaceutical R&D: The Process Behind New Medicines (Pharmaceut. Res. Manufact. Am., 2015).
Feng, K. et al. Nature 580, 621–627 (2020).
Article Google Scholar
Schönherr, H. & Cernak, T. Angew. Chem. Int. Edn 52, 12256–12267 (2013).
Article Google Scholar
Moir, M., Danon, J. J., Reekie, T. A. & Kassiou, M. Expert Opin. Drug Discov. 14, 1127–1149 (2019).
Article Google Scholar
Cernak, T., Dykstra, K. D., Tyagarajan, S., Vachal, P. & Krska, S. W. Chem. Soc. Rev. 45, 546–576 (2019).
Article Google Scholar
Sono, M., Roach, M. P., Coulter, E. D. & Dawson, J. H. Chem. Rev. 96, 2841–2888 (1996).
Article PubMed Google Scholar
Denisov, I. G., Makris, T. M., Sligar, S. G. & Schlichting, I. Chem. Rev. 105, 2253–2278 (2005).
Article PubMed Google Scholar
Chen, M. S. & White, C. Science 318, 783–787 (2007).
Article PubMed Google Scholar
Zhao, J., Nanjo, T., de Lucca, E. C. & White, M. C. Nature Chem. 11, 213–221 (2019).
Article PubMed Google Scholar